Stock data
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN) reported net income of -US$69.69M for fiscal 2026. The figures below come from the company's SEC filings.
Annual results
Data as of 2026-03-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | — | — | -US$72.13M | -US$69.69M | — |
| 2025 | — | — | -US$55.97M | -US$51.42M | — |
| 2024 | — | — | -US$33.02M | -US$29.36M | — |
| 2023 | -US$0.23M | — | -US$59.27M | -US$59.25M | — |
| 2022 | US$1.11M | — | -US$47.78M | -US$47.76M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$13.03M | — |
| 2026-03-31 | — | -US$16.27M | — |
| 2025-12-31 | — | -US$18.90M | — |
| 2025-09-30 | — | -US$19.42M | — |
| 2025-06-30 | — | -US$15.10M | — |
| 2025-03-31 | — | -US$13.63M | — |
| 2024-12-31 | — | -US$14.09M | — |
| 2024-09-30 | — | -US$12.96M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.